Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis

研究成果: ジャーナルへの寄稿評論記事

46 引用 (Scopus)

抄録

Atopic dermatitis (AD) is a chronic or chronically relapsing, eczematous, severely pruritic skin disorder associated with skin barrier dysfunction. The lesional skin of AD exhibits T helper 2 (TH2)-deviated immune reactions. Interleukin-31 (IL-31), preferentially produced from TH2 cells, is a potent pruritogenic cytokine, and its systemic and local administration induces scratching behavior in rodents, dogs and monkeys. Recent clinical trials have revealed that administration of an anti-IL-31 receptor antibody significantly alleviates pruritus in patients with AD. In this review, we summarize recent topics related to IL-31 and its receptor with special references to atopic itch.

元の言語英語
ページ(範囲)29-36
ページ数8
ジャーナルAllergy: European Journal of Allergy and Clinical Immunology
73
発行部数1
DOI
出版物ステータス出版済み - 1 2018

Fingerprint

Interleukin Receptors
Interleukins
Atopic Dermatitis
Pruritus
Skin
Th2 Cells
Haplorhini
Rodentia
Clinical Trials
Dogs
Cytokines
Antibodies

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

これを引用

@article{0bafa651589e4928a8a13cb765a1ce1f,
title = "Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis",
abstract = "Atopic dermatitis (AD) is a chronic or chronically relapsing, eczematous, severely pruritic skin disorder associated with skin barrier dysfunction. The lesional skin of AD exhibits T helper 2 (TH2)-deviated immune reactions. Interleukin-31 (IL-31), preferentially produced from TH2 cells, is a potent pruritogenic cytokine, and its systemic and local administration induces scratching behavior in rodents, dogs and monkeys. Recent clinical trials have revealed that administration of an anti-IL-31 receptor antibody significantly alleviates pruritus in patients with AD. In this review, we summarize recent topics related to IL-31 and its receptor with special references to atopic itch.",
author = "M. Furue and K. Yamamura and M. Kido-Nakahara and T. Nakahara and Y. Fukui",
year = "2018",
month = "1",
doi = "10.1111/all.13239",
language = "English",
volume = "73",
pages = "29--36",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis

AU - Furue, M.

AU - Yamamura, K.

AU - Kido-Nakahara, M.

AU - Nakahara, T.

AU - Fukui, Y.

PY - 2018/1

Y1 - 2018/1

N2 - Atopic dermatitis (AD) is a chronic or chronically relapsing, eczematous, severely pruritic skin disorder associated with skin barrier dysfunction. The lesional skin of AD exhibits T helper 2 (TH2)-deviated immune reactions. Interleukin-31 (IL-31), preferentially produced from TH2 cells, is a potent pruritogenic cytokine, and its systemic and local administration induces scratching behavior in rodents, dogs and monkeys. Recent clinical trials have revealed that administration of an anti-IL-31 receptor antibody significantly alleviates pruritus in patients with AD. In this review, we summarize recent topics related to IL-31 and its receptor with special references to atopic itch.

AB - Atopic dermatitis (AD) is a chronic or chronically relapsing, eczematous, severely pruritic skin disorder associated with skin barrier dysfunction. The lesional skin of AD exhibits T helper 2 (TH2)-deviated immune reactions. Interleukin-31 (IL-31), preferentially produced from TH2 cells, is a potent pruritogenic cytokine, and its systemic and local administration induces scratching behavior in rodents, dogs and monkeys. Recent clinical trials have revealed that administration of an anti-IL-31 receptor antibody significantly alleviates pruritus in patients with AD. In this review, we summarize recent topics related to IL-31 and its receptor with special references to atopic itch.

UR - http://www.scopus.com/inward/record.url?scp=85025435358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025435358&partnerID=8YFLogxK

U2 - 10.1111/all.13239

DO - 10.1111/all.13239

M3 - Review article

C2 - 28670717

AN - SCOPUS:85025435358

VL - 73

SP - 29

EP - 36

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

SN - 0105-4538

IS - 1

ER -